Biomarkers for Endometriosis

Sponsor
Trio Fertility
Study ID
NCT07713797
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Accepted

Interventions

  • SNCG Protein — DIAGNOSTIC_TEST
    Synuclein gamma (SNCG), a member of the synuclein family of neuronal proteins, is involved in cellular proliferation by interacting with the mitotic checkpoint kinase BubR1, and inhibiting its regulatory role on cellular proliferation. During the last decade, several studies have demonstrated that SNCG is correlated with poor outcome of breast cancer, ovarian cancer, colon cancer and pancreatic cancer. Interestingly, SNCG has previously been shown to have elevated expression ranging from 5- to 53-fold in ovarian endothelial cells of endometriosis lesions compared with eutopic endometrium from the same individual.
  • BCL-6 Protein — DIAGNOSTIC_TEST
    B-Cell Lymphoma 6 (BCL6) protein is encoded by the BCL6 oncogene and is a zinc finger transcription factor that regulates the transcription of signal transducer and activators of transcription (STAT)-dependent IL-4 responses of B-cells. Previously, BCL6 was shown to express in the endometrial epithelial cells and B-cells in lymph node germinal centers. In addition, over-expression of BCL6 has been reported in endometrial biopsies and has been linked to the progesterone resistance and pathogenesis of endometriosis

Study Details

Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, often causing pain and infertility. Currently, endometriosis can only be definitively diagnosed through invasive procedures like laparoscopy and biopsy. The purpose of this study is to investigate whether the proteins Synuclein Gamma (SNCG) and B-Cell Lymphoma 6 (BCL6), measurable in blood and menstrual fluid, can serve as non-invasive biomarkers to diagnose or monitor endometriosis.

Key Dates

First listed
Jul 20, 2026
Start date
Jan 16, 2026
Status verified
Jul 2026
Primary completion
Jan 1, 2027
Completion
Sep 1, 2027

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Endometriosis Group
    Patients who have been diagnosed with Endometriosis
  • Arm: Control Group
    Patients who have not been diagnosed with Endometriosis

Primary Outcome Measure

SNCG and BCL-6 Levels [ Time Frame: Baseline for control participants and baseline and approximately 3 months after treatment for participants with endometriosis ]

Central Contacts

Find similar trials

Nationwide
Endometriosis trialsWomen's health trialsFertility trials

Related Studies